European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The H4-Index of European Heart Journal-Cardiovascular Pharmacotherapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure47
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-1947
Prevention is still the key to success40
Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested c39
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis35
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?34
Response: Letter to the editor30
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries29
Oral anticoagulants and antiplatelet treatment in different settings29
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity29
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation28
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE228
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases26
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials25
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials23
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk23
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate22
Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis22
More knowledge about atrial fibrillation, still we need to learn22
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure21
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics21
Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction21
0.058336973190308